{"denoms":[{"counts":[{"groupId":"BG000","value":"134"},{"groupId":"BG001","value":"69"},{"groupId":"BG002","value":"64"},{"groupId":"BG003","value":"31"},{"groupId":"BG004","value":"298"}],"units":"Participants"}],"groups":[{"description":"Patients receive cabozantinib S-malate PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT, MRI, and/or x-ray imaging during screening and on study.\\>\n\n\\> Cabozantinib S-malate: Given PO\\>\n\n\\> Computed Tomography: Undergo CT\\>\n\n\\> Magnetic Resonance Imaging: Undergo MRI\\>\n\n\\> Quality-of-Life Assessment: Ancillary studies\\>\n\n\\> X-Ray Imaging: Undergo x-ray","id":"BG000","title":"Arm Ia (Cabozantinib S-malate, Extra-pancreatic NET Cohort [epNET])"},{"description":"Patients receive placebo PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT, MRI, and/or x-ray imaging during screening and on study. Patients may crossover to receive cabozantinib S-malate at the time of disease progression.\\>\n\n\\> Computed Tomography: Undergo CT\\>\n\n\\> Magnetic Resonance Imaging: Undergo MRI\\>\n\n\\> Placebo Administration: Given PO\\>\n\n\\> Quality-of-Life Assessment: Ancillary studies\\>\n\n\\> X-Ray Imaging: Undergo x-ray","id":"BG001","title":"Arm IIa (Placebo, Extra-pancreatic NET Cohort [epNET])"},{"description":"Patients receive cabozantinib S-malate PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT, MRI, and/or x-ray imaging during screening and on study.\\>\n\n\\> Cabozantinib S-malate: Given PO\\>\n\n\\> Computed Tomography: Undergo CT\\>\n\n\\> Magnetic Resonance Imaging: Undergo MRI\\>\n\n\\> Quality-of-Life Assessment: Ancillary studies\\>\n\n\\> X-Ray Imaging: Undergo x-ray","id":"BG002","title":"Arm Ib (Cabozantinib S-malate, Pancreatic NET Cohort [pNET])"},{"description":"Patients receive placebo PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT, MRI, and/or x-ray imaging during screening and on study. Patients may crossover to receive cabozantinib S-malate at the time of disease progression.\\>\n\n\\> Computed Tomography: Undergo CT\\>\n\n\\> Magnetic Resonance Imaging: Undergo MRI\\>\n\n\\> Placebo Administration: Given PO\\>\n\n\\> Quality-of-Life Assessment: Ancillary studies\\>\n\n\\> X-Ray Imaging: Undergo x-ray","id":"BG003","title":"Arm IIb (Placebo, Pancreatic NET Cohort [pNET])"},{"description":"Total of all reporting groups","id":"BG004","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"28","upperLimit":"86","value":"66"},{"groupId":"BG001","lowerLimit":"30","upperLimit":"82","value":"66"},{"groupId":"BG002","lowerLimit":"29","upperLimit":"79","value":"59.5"},{"groupId":"BG003","lowerLimit":"39","upperLimit":"79","value":"64"},{"groupId":"BG004","lowerLimit":"28","upperLimit":"86","value":"66"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"74"},{"groupId":"BG001","value":"31"},{"groupId":"BG002","value":"27"},{"groupId":"BG003","value":"13"},{"groupId":"BG004","value":"145"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"60"},{"groupId":"BG001","value":"38"},{"groupId":"BG002","value":"37"},{"groupId":"BG003","value":"18"},{"groupId":"BG004","value":"153"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"21"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"125"},{"groupId":"BG001","value":"56"},{"groupId":"BG002","value":"61"},{"groupId":"BG003","value":"26"},{"groupId":"BG004","value":"268"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"9"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"8"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"22"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"115"},{"groupId":"BG001","value":"55"},{"groupId":"BG002","value":"54"},{"groupId":"BG003","value":"25"},{"groupId":"BG004","value":"249"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"16"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"134"},{"groupId":"BG001","value":"69"},{"groupId":"BG002","value":"64"},{"groupId":"BG003","value":"31"},{"groupId":"BG004","value":"298"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"}]}